Related Experiment Videos
[New hypoglycemic drugs in treatment of diabetes type 2]
1Katedra i Klinika Gastroenterologii i Chorób Wewnetrznych Akademii Medycznej im. Ludwika Rydygiera w Bydgoszczy.
Abstract:
Diabetes mellitus type 2 is a syndrome with different etiopathology and clinical picture. Results of clinical studies show that hyperglycaemia increases during the time of diabetes even if it is intensively treated. At the present time some new hypoglycaemic drugs have been introduced for type 2 diabetes mellitus therapy. These drugs can increase insulin secretion by the inhibition of the ATP-sensitive K+ channels (glimepyride, repaglinide) or by incretin action (glucagon-like peptide-1). Other drugs can decrease insulin resistance acting on nuclear receptors (troglitazone). Normalization of stomach motoric activity can also lead to decreasing of blood glucose concentration (pramlintid). Also other mechanisms of action are taken into consideration, like changing of cytokine activity or catabolism regulation of beta-cells of the Langerhans' islets.
Insights
Type 2 diabetes is a complex syndrome where high blood sugar persists despite treatment. New therapies target insulin secretion, resistance, and stomach activity to manage hyperglycemia.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Context:
- Type 2 diabetes mellitus (T2DM) is characterized by progressive hyperglycemia, often inadequately controlled by existing treatments.
- The syndrome presents with diverse etiopathologies and clinical manifestations.
Purpose:
- To review novel hypoglycemic agents for T2DM therapy.
- To explore diverse mechanisms of action for blood glucose regulation in T2DM.
Summary:
- New T2DM drugs enhance insulin secretion via ATP-sensitive K+ channel inhibition (e.g., glimepiride) or incretin action (e.g., glucagon-like peptide-1).
- Other agents reduce insulin resistance through nuclear receptor modulation (e.g., troglitazone) or normalize gastric motility (e.g., pramlintide).
- Emerging therapeutic strategies also consider modulating cytokine activity and regulating beta-cell catabolism.
Impact:
- Provides an overview of advanced pharmacological interventions for T2DM management.
- Highlights the expanding therapeutic landscape for achieving glycemic control in T2DM patients.
- Facilitates understanding of multifaceted approaches to combatting persistent hyperglycemia in T2DM.